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Chapter 14
Intensivmedizin – Leitlinie Parenterale Ernährung, Kapitel 14
Abstract
Inintensivecarepatientsparenteralnutrition(PN)shouldnotbecarried
out when adequate oral or enteral nutrition is possible. Critically ill pa-
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5 PN but should be given at least a basal supply of glucose. Critically ill
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sive care if they are unlikely to be adequately nourished orally or enter-
allyevenafter5–7days.Criticallyillandmalnourishedpatientsshould,
guidelines for in addition to a possible partial enteral nutrition, be nourished par-
parenteral nutrition of enterally. Energy supply should not be constant, but should be adapted
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should be given, as PN, a mixture consisting of amino acids (between
0.8 and 1.5 g/kg/day), carbohydrates (around 60% of the non-protein
energy) and fat (around 40% of the non-protein energy) as well as
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EineparenteraleErnährung(PE)solltenichtdurchgeführtwerden,wenn
eine ausreichende orale oder enterale Ernährung möglich ist. Kritisch
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vollen PE, sollten aber zumindest eine basale Glukosezufuhr erhalten.
Kritisch Kranke sollten von Anbeginn der Intensivtherapie parenteral
ernährt werden, wenn sie voraussichtlich auch nach einem Zeitraum
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von 5–7 Tagen nicht ausreichend oral oder enteral ernährt werden
können. Kritisch Kranke mit einer Mangelernährung sollten – auch
neben einer möglichen partiellen enteralen Ernährung – parenteral er-
nährt werden. Die Energiezufuhr sollte nicht konstant sein, sondern
muss an den Verlauf der Erkrankung angepasst werden. Eine Hyperali-
mentation sollte im akuten Stadium der Erkrankung auf jeden Fall ver-
mieden werden. Kritisch Kranke sollten zur PE eine Mischung aus
Aminosäuren (0,8 und 1,5 g/kg/Tag), Kohlenhydraten (ca. 60% der
Nicht-ProteinEnergie)undFett(ca.40%derNicht-ProteinEnergie)sowie
Elektrolyten und Mikronährstoffen erhalten.
Schlüsselwörter:Substratzufuhr,kritischkrank,Sepsis,Intensivtherapie
Indications for PN in critically ill
patients
• Parenteralnutrition(PN)shouldnotbeinstitutedwhen
adequate oral or enteral nutrition is possible (C).
• Criticallyillpatientswithoutsymptomsofmalnutrition,
whoprobablycannotbeadequatelynourishedenterally
for a period of <5 days, do not require full PN but
should be given at least a basal supply of glucose (B).
Commentary
Patients who can be nourished orally or enterally should
certainly be nourished this way.
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studies[1]probablyoccurredasaresultofunphysiologic
composition and infrequent monitoring of PN (too high
energy used, badly monitored BS (blood sugar) levels)
ratherthanbecauseoftheparenteralsubstrateadminis-
tration.Recentstudies[2],[3]haveshownthat,compared
with enteral nutrition, there is not necessarily a connec-
tion between PN and a higher rate of complications or a
worse prognosis.
Nevertheless, it is concluded by the expert group that
enteral application should be preferred, if possible, as it
ismorephysiological,andgenerallyincurringlowercosts.
Furthermore, with the exception of one study, PN did not
have specific advantages over enteral nutrition.
There are still not enough randomised controlled studies
to answer the question whether patients should be fed
parenterally when they cannot be adequately enterally
nourished.
Experiencesoverthelastyearshaveshownthatifenteral
nutrition is started early, a higher proportion of patients,
requiring intensive care, can be adequately nourished
enterally after a few days. In one such study [4], it was
observed that a reduced nutrition supply over a few days
had no negative consequences, as long as the patients
showed no symptoms of malnutrition. Adequately nour-
ished patients who can be completely nourished orally
or enterally again within 5–7 days do not require PN. For
suchpatients,oneshouldprovideatleastabasalglucose
supply (2–3 g/kg kg/day). However, for malnourished
patients one should start early with PN.
Indication for PN
• Critically ill patients should be nourished parenterally
fromthebeginningofintensivecareiftheyareunlikely
to be adequately nourished orally or enterally even
after 5–7 days (A).
Commentary
Intheabove-mentionedstudy[4],theelectivelyoperated
patients, who were given infusions of only 250–300 g
glucose/day and were unable to take adequate nourish-
ment orally after 14 days, showed a 10 times higher
mortality than patients who were nourished completely
parenterally from the beginning of intensive care. There-
fore, post-operative patients who might develop a state
of malnutrition, after a period of 8–12 days on only
glucose infusions, may be predisposed to a higher rate
of mortality. Since it should not be the aim of nutrition
therapy to allow the patients to get into a state of malnu-
trition and then be treated for it, such patients should be
nourished parenterally from the beginning of intensive
care.
Accordingly, the indication for PN should be made pro-
spectively in critically ill parents. The number of days re-
quired to re-establish adequate enteral or oral nutrition
should be considered at the beginning of the therapy.
Thereare,atpresent,noestablishedcriteria,whichcould
help in determining, with absolute certainty, which pa-
tients are to be nourished parenterally. Therefore, it
cannot be avoided that occasionally there are patients
on PN who are adequately nourished enterally sooner
than expected, and some patients who unexpectedly de-
teriorate and an indication for PN is established too late.
Combinednutritiontherapy(enteraland
parenteral nutrition)
• Critically ill and malnourished patients should, in add-
ition to a possible partial enteral nutrition, be nour-
ished parenterally (A).
Commentary
Several studies dealing with patients suffering from
severemalnutrition,whichhavebeensummarizedinone
meta-analysis [1], have reported a positive effect of PN
with a reduction in complications and mortality.
Energy intake
• The amount of energy supplied should follow the
principlesstatedinthechapteron“Energyexpenditure
and energy intake” http://www.egms.de/en/gms/
2009-7/000084.shtml.
Thismeansthattheenergysupplyshouldnotbeconstant,
but should be adapted to the stage, the disease has
reached. Hyper-alimentation should be avoided at an
acute stage of disease in any case.
Substrate intake
• Critically ill patients should be given, as PN, a mixture
consistingofaminoacids,carbohydrates,(around60%
of the non-protein energy) and fat (around 40% of the
non-proteinenergy)aswellaselectrolytesandmicronu-
trients (C).
Commentary
Typical metabolic changes in patients with systemic in-
flammatory reactions are a reduced oxidation of carbo-
hydratesandanincreasedoxidationoffat.Thedispropor-
tionbetweenendogenousglucoseproductionandperiph-
eral glucose oxidation leads to hyperglycaemia in most
patients. Accordingly, a lipid supply of 30–50% of energy
intake corresponds to the existing pattern of utilization.
An increased glucose intake, in such circumstance, does
not reduce the endogenous glucose production [5], and
leads to a further increase in the already existing hyper-
glycaemia.
However, it has not been substantiated by studies
whether in critically ill patients PN with lipids, and with
which kind of lipids, would be more effective than a
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comeparameters.Therefore,therecommendationofthe
group to give PN containing fat to critically ill patients is
only an expert opinion (C).
The comparative study of Batistella [6], which showed
obvious disadvantages when lipids were administered to
trauma patients has the following shortcomings: a) not
isocaloric in both arms of the study (the energy contents
in patients without lipids was about 25% lower) and b)
soya bean oil/lipid emulsion was used in the study, the
use of which is nowadays controversial for patients in a
critical state (see below). Similarly, the higher rate of
complications that has been found in the meta-analysis
of Heyland et al. [7] for patients given lipid infusions is
more a result of the special fat emulsion used than the
fat administration in general.
Carbohydrates
(cf.“Carbohydrates”http://www.egms.de/en/gms/2009-
7/000082.shtml)
• Critically ill patients should predominantly be given
glucoseascarbohydrate.Thereisnocertainindication
for other carbohydrates in critically ill patients (C).
Commentary
Fructose and sorbitol are no longer used because of the
gravesideeffectswhenthereisaninbornincompatibility.
With Xylit, a reduction of hyperglycaemia as well as a de-
crease in hepatic gluconeogenesis was shown in two
clinical studies on a small number of patients, when
glucose intake was simultaneously decreased. These
results have not been confirmed in any further major
study. This group does not recommend the use of Xylit,
particularly in consideration of observed complications
(oxalose).
Hyperglycaemia arising from PN
(cf.“Carbohydrates”http://www.egms.de/en/gms/2009-
7/000082.shtml and “Complications and monitoring”
http://www.egms.de/en/gms/2009-7/000076.shtml)
• At all times, a hyperglycaemia caused by PN should
be avoided (A).
• If hyperglycaemia occurs, in spite of an adequate in-
sulin supply, the carbohydrate supply should be re-
duced (C).
Commentary
The study of van den Berghe et al. [8] showed that, for
patients requiring intensive care, blood sugar levels of
over 110 mg/dl are linked to a significant increase in
mortalityandmorbidity.Insulincanreducebloodglucose
level through an increase in cellular glucose uptake and
partly through increased glucose utilization as well. The
insulin effect can, however, be reduced in particular ill-
nesses such as diabetes mellitus, post-operative insulin
resistance, or sepsis.
There were indications in a more recent uncontrolled
observational study, that a significantly higher mortality
was observed only at blood sugar concentration of >145
mg/dl [9]. In the controlled study from van den Berghe,
however, in the group of patients with blood sugar levels
between110–150mg/dltherewasalreadyasignificantly
higher mortality than in the group of patients in which
blood sugar was strictly controlled at values below 110
mg/dl [10]. Therefore, the objective should be to aim for
a normoglycaemia with PN, ideally a level between 80
and 110 mg/dl.
Basically two situations can occur:
a) Patients who are euglycaemic before the start of a PN:
If there is a significant increase in the blood sugar level
to a value considerably >110 mg/dl, while an adequate
substrate supply is being administered during the PN,
thenthisshouldbeloweredwithacontinuousintravenous
insulin administration, by means of an infusion pump. It
isrecommendedtohaveastandardisedprotocolaccord-
ing to which the insulin dose can be regulated in accord-
ance with the measured blood glucose levels.
If normoglycaemia (<145 mg/dl, ideally <110 mg/dl) is
not achieved, even with a maximum insulin dose of ap-
proximately20IUinsulin/h,thenthecarbohydratesupply
should be reduced until the target BS level is attained
using this insulin dose. The maximum level of approxi-
mately 20 IU insulin/h is not substantiated by any study
but is an expert opinion.
If the BS falls to a level <80 mg/dl with this therapy, then
the carbohydrate intake should be increased again until
thetargetcarbohydrateintakeforeuglycaemicconditions
is achieved.
If the BS level falls at the maximum (=target) value of
carbohydrate intake, the insulin dose should be lowered.
b) Patients with a BS level >110 mg/dl before commen-
cing PN:
Forthesepatients,hyperglycaemiaisaresultofadispro-
portional rate of endogenous gluconeogenesis and glu-
cose oxidation. It is not recommended, under these con-
ditions, to infuse even more glucose as this would only
augment the hyperglycaemia.
Forthisreason,oneshouldstartwithacontinuousinsulin
infusion. Only when the target BS level can be reached
andmaintainedwithadoseof≤4IUinsulin/h,oneshould
start with an additional glucose supply.
Fats
• No choice of specific fat emulsion is recommended
for critically ill patients, because there are no conclu-
sive clinical studies on varying endpoint effects of dif-
ferent lipid emulsions.
• A preferential use of lipid emulsions with a lower con-
tent of polyunsaturated fatty acids, relative to pure
soybean oil emulsions, appears justifiable in critically
ill patients (C).
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A large number of clinical, ex-vivo and animal studies
haveshownthatthequalityoftheinfusedfattyacidshas
aclinicallyrelevanteffectsontheimmunesystem.Itwas
observed that classic soybean oil emulsions suppressed
thecellularimmuneresponseandstimulatedtherelease
of interleukins with a pro-inflammatory pattern. One clin-
ical study [6] has also demonstrated that soybean oil
emulsions not affect killer cell activity but also induce a
higherrateofinfectionandlongerdurationofmechanical
ventilation and treatment. However, in this study the
control group did not receive isocaloric nutrition.
The existing experimental data as well as this clinical
study appear to justify the recommendation not to con-
sider pure soybean oil emulsions as the lipid emulsion
of choice for critically ill patients.
Alternatives are mixtures consisting of soybean oil and
MCT, a mixture consisting of soybean oil or soybean oil
/MCT and fish oil, a mixture consisting of 20% soybean
oil and 80% olive oil, or a mixture consisting of soybean
oil, MCT, olive oil and fish oil, or a mixture consisting of
soybean oil, MCT and fish oil. In addition, an emulsion is
available with re-esterified medium- and long-chain fatty
acids.
No clinical studies have been published to demonstrate
an obvious advantage of one of these emulsions over
others with respect to relevant clinical outcome param-
eters in critically ill patients.
Amino acids
• The amino acid intake with PN for critically ill patients
should usually be between 0.8 and 1.5 g/kg/day (A).
Commentary
In several clinical studies it was observed that an amino
acid infusion of more than 1.5 g/kg/day does not lead
toabetternitrogenbalance,butinsteadtoanaugmented
ureaproduction[11],[12],[13],[14],[15],[16].Although
thislevelhasbeenquestionedrecentlybyseveralauthors
[17], [18], on the basis of the existing data it is recom-
mended to supply parenteral amino acids between 0.8
and1.5g/kgbodyweightdaily.Certaingroupsofpatients
(e.g.patientswithburns,patientswithrenalfailure)need
a higher infusion of amino acids.
Glutamine
• Critically ill patients who are nourished parenterally
forlongerthan5days,withoutreceivinganysignificant
nutrition enterally, should be given, in addition to the
parenteralinfusionofaminoacids,glutaminedipeptide
inadoseof0.3–0.4g/kgbodyweight/day(equivalent
to 0.2–0.26 g glutamine/kg body weight/day) (A).
Commentary
A meta-analysis [19] published in 2002 found that a
glutamine supplementation leads to a lower rate of
complicationsandadecreaseinmortalityrateincritically
ill patients. However, the validity of this meta-analysis is
limited because it was an evaluation of studies in which
both parenteral and enteral glutamine supplementation
studieswereevaluatedtogether.Furthermore,therewas
one study dealing only with burn patients [20].
Afterthepublicationoftheabovemeta-analysis,twomore
studieswerepublished,inwhichcriticallyillpatientswere
administeredadditionalglutamineparenterally[21],[22].
The investigation by Goeters et al. [22] showed that for
patients who were treated with 0.2 g glutamine/kg body
weight/day for a period of ≥9 days, the mortality over a
period of 6 months could be reduced significantly from
66.7% to 40%. These results confirm the results of Grif-
fithsetal.[23],wheresignificantimprovementinsurvival
at 6 months was observed mainly in those patients who
were treated with glutamine for more than 5 days.
Another study, however, published in 2004 showed in
patients with secondary peritonitis [21] only a tendency
to a decreased mortality with parental supplementation
of glutamine. This was also observed by the study of
Powell-Tuck et al. [24] with patients clinically accepted
for PN. On the basis of the results of these four studies,
it is concluded that a solution of amino acids enriched
with glutamine dipeptides should be used at least in pa-
tients who need PN for more than 5 days,
Branched-chain amino acids
• In critically ill patients, there is no firm indication for
the use of amino acids solutions with a higher propor-
tionofbranched-chainaminoacids,exceptforpatients
with severe hepatic encephalopathy (C).
Commentary
The published small studies [25], [26], [27] using amino
acid solutions with an increased proportion of branched-
chain amino acids in critically ill patients did not show
any advantages in outcome parameters till to date.
The expert group does not see a concrete indication for
theuseofsuchasolutionatpresent,sinceamajorstudy
on this is not yet published.
Notes
This article is part of the publication of the Guidelines on
Parenteral Nutrition from the German Society for Nutri-
tional Medicine (overview and corresponding address
under http://www.egms.de/en/gms/2009-7/000086.
shtml).
English version edited by Sabine Verwied-Jorky, Rashmi
Mittal and Berthold Koletzko, Univ. of Munich Medical
Centre, Munich, Germany.
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